EPHA3 and cancer: EphA3 cancer somatic mutations are distributed throughout the domains of the receptor and some have been shown to impair ephrin ligand-dependent receptor signaling, suggesting a tumor suppressor role for the EphA3/ephrin interaction, which has been substantiated by functional studies [4–6].